ACADIA Pharmaceuticals Inc.
ACAD
Rang în acțiuni
#4507
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Preț acțiune
$19.76
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$3.40B
Schimbare (1 zi)
3.32%
Schimbare (1 an)
-5.66%
Țară
US
Tranzacționează ACADIA Pharmaceuticals Inc. (ACAD)
Categorie
Healthcare
Raport P/S pentru ACADIA Pharmaceuticals Inc. (ACAD)
Raport P/S la data de October 2026 TTM: 2.89
Conform celor mai recente rapoarte financiare și prețului acțiunilor ACADIA Pharmaceuticals Inc., raportul P/S actual (TTM) este 2.89. La sfârșitul anului 2023, compania avea un P/S de 7.06.
Istoricul raportului P/S pentru ACADIA Pharmaceuticals Inc. din 2000 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 2.89 | -8.68% |
| 2024 | 3.17 | -55.03% |
| 2023 | 7.06 | 41.88% |
| 2022 | 4.98 | -35.68% |
| 2021 | 7.74 | -59.36% |
| 2020 | 19.04 | 2.52% |
| 2019 | 18.57 | 103.07% |
| 2018 | 9.15 | -69.06% |
| 2017 | 29.56 | -84.67% |
| 2016 | 192.80 | -99.67% |
| 2015 | 58.81K | 128.57% |
| 2014 | 25.73K | 1,275.39% |
| 2013 | 1.87K | 3,498.15% |
| 2012 | 51.99 | 90.69% |
| 2011 | 27.27 | 2,380.70% |
| 2010 | 1.10 | -85.78% |
| 2009 | 7.73 | -63.20% |
| 2008 | 21.01 | -59.28% |
| 2007 | 51.59 | 70.96% |
| 2006 | 30.18 | 52.49% |
| 2005 | 19.79 | 30.01% |
| 2004 | 15.22 | 1,049.01% |
| 2003 | 1.32 | -14.53% |
| 2002 | 1.55 | -28.86% |
| 2001 | 2.18 | 31.07% |
| 2000 | 1.66 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | 246.20% |
US
|
|
| 40.55 | 1,300.77% |
US
|
|
| 3.96 | 36.83% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 250.49% |
NL
|
